These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 31551166

  • 1. [Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score].
    Giner-Soriano M, Casajuana M, Roso-Llorach A, Vedia C, Morros R.
    Aten Primaria; 2020 Mar; 52(3):176-184. PubMed ID: 31551166
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
    Anguita Sánchez M, Bertomeu Martínez V, Ruiz Ortiz M, Cequier Fillat Á, Roldán Rabadán I, Muñiz García J, Badimón Maestro L, Esteve Pastor MA, Marín Ortuño F, FANTASIIA study investigators.
    Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
    [Abstract] [Full Text] [Related]

  • 6. Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).
    Vinereanu D, Napalkov D, Bergler-Klein J, Benczur B, Ciernik M, Gotcheva N, Medvedchikov A, Põder P, Simic D, Skride A, Tang W, Trusz-Gluza M, Vesely J, Vishnepolsky T, Vrabec M.
    Open Heart; 2020 Jan; 7(1):e001202. PubMed ID: 32257246
    [Abstract] [Full Text] [Related]

  • 7. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G, Billionnet C, Alla F, Gagne JJ, Pariente A.
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation.
    Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N.
    Br J Clin Pharmacol; 2019 Feb; 85(2):432-441. PubMed ID: 30423205
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
    Sigismondi A, Camacho-Freire SJ, León-Jiménez J, Isasti-Aizpurva G, García-Lizana MD, Morgado-García de Polavieja JI, Caro-Fernández FJ, Roa-Garrido J, Navarro-Roldán F, Díaz-Fernández JF.
    Arch Cardiol Mex; 2019 Feb; 89(4):382-392. PubMed ID: 31834326
    [Abstract] [Full Text] [Related]

  • 11. Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.
    Pallisgaard JL, Gislason GH, Torp-Pedersen C, Lee CJ, Sindet-Pedersen C, Staerk L, Olesen JB, Lindhardt TB.
    PLoS One; 2016 Feb; 11(8):e0161768. PubMed ID: 27560967
    [Abstract] [Full Text] [Related]

  • 12. Antithrombotic Usage, Including Three-Year Outcomes With Dabigatran and Vitamin K Antagonists for Atrial Fibrillation, in Eastern Europe: A Descriptive Analysis From Phase 3 of the GLORIA-AF Registry.
    Bergler-Klein J, Gotcheva N, Kalējs O, Kalarus Z, Kovačić D, Peršić V, Shlyakhto E, Uuetoa T, Huisman MV, Lip GYH, Vinereanu D, GLORIA-AF Investigators.
    Am J Ther; 2016 Feb; 31(1):e1-e12. PubMed ID: 38231576
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database.
    Giner-Soriano M, Roso-Llorach A, Vedia Urgell C, Castells X, Capellà D, Ferreira-González I, Elorza-Ricart JM, Casajuana M, Troncoso Mariño A, Diògene E, Bolíbar B, Violan C, Morros R.
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):97-107. PubMed ID: 27868275
    [Abstract] [Full Text] [Related]

  • 19. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.
    Go AS, Singer DE, Toh S, Cheetham TC, Reichman ME, Graham DJ, Southworth MR, Zhang R, Izem R, Goulding MR, Houstoun M, Mott K, Sung SH, Gagne JJ.
    Ann Intern Med; 2017 Dec 19; 167(12):845-854. PubMed ID: 29132153
    [Abstract] [Full Text] [Related]

  • 20. [Pharmaco-utilization and outcomes in patients treated with oral anticoagulants from 2014 to 2015: evidences from administrative databases of the Romagna Local Health Unit].
    Degli Esposti L, Perrone V, Saragoni S, Buda S, Piovaccari G.
    G Ital Cardiol (Rome); 2020 Jan 19; 21(1):25-33. PubMed ID: 31960832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.